Camlin Fine Sciences Limited — PPTs, 08-08-2025: Investor Presentation

Here is the financial summary for Camlin Fine Sciences Limited:

**1. Financial Highlights:**

Q1FY26 consolidated revenue was Rs 428.6 Cr, a sequential dip. Adjusted EBITDA sharply fell to Rs 19.0 Cr (4.5% margin) from Rs 59.4 Cr (13.6%), primarily due to sluggish Specialty Ingredients Straights. Blends business showed strong growth. Consolidated PAT resulted in a Rs 10.68 Cr loss.

**2. Strategic Initiatives & Growth Drivers:**

The company strengthens its market position through expansions, focusing on high-value blends and Vanillin via vertical integration. Product development prioritizes specialized chemicals and continuous antioxidant innovations, with many new specialty ingredients expected in FY26.

**3. Business Developments:**

Key developments include the recent CFS Vitafor acquisition. The company consistently prioritizes high-value blends and additives, serving diverse global industries like Food & Beverage and Animal Nutrition.

**4. Market Position & Competitive Advantage:**

As a global leader in antioxidants and customized shelf-life solutions, the company leverages integrated global production, its Vanillin range, strong vertical integration, and continuous innovation for its competitive edge.

**5. Investor Implications:**

Despite Q1FY26's revenue dip and margin pressure from 'straights' demand, robust blends growth and strategic initiatives indicate positive growth potential. Investors should monitor 'straights' market recovery and new product commercialization.